The partnership pairs Pillar's portfolio of oncoReveal (R) kitted NGS panels with CellCarta's global laboratory network and biomarker expertise to reduce screening friction, improve turnaround time, ...

The rapid evolution of HIV under antiretroviral pressure necessitates ongoing surveillance of drug resistance mutations. Next-generation sequencing (NGS) has emerged as a transformative technology in ...

Next-generation sequencing (NGS), especially long-read DNA sequencing, is transforming infectious organism detection by ...

Enabled by its exclusive license of CoolMPS technology, Swiss Rockets AG is developing its first sequencer, CoolMPS 600, through contract R&D with Complete Genomics since August 2025. The platform is ...

Pattern of resistance on first-line EGFR-directed therapy in EGFR-positive metastatic non-small cell lung cancer. Utilizing TP53 mutation status and initial disease burden at presentation to ...

Eric Green, MD, PhD, Chief Medical Officer of Illumina, was awarded the Distinguished Service Award by board members of The Genome Partnership—the nonprofit organization that has organized the ...

Cost-effectiveness of NTRK testing strategies for detecting NTRK fusions in solid tumors in China.

Brian Tait calls for public support to fund exciting groundbreaking technology for assigning phase to multiple mutations ...

-- Milestone marks first of multiple planned diagnostic product launches on NGS roadmap -- Powered by the Archer platform technology, IDT empowers molecular pathology laboratories with first in vitro ...